Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trial-Reference-Cited by-同舟云学术

Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trial

Published:2002-06 Issue:9323 Volume:359 Page:2065-2071
ISSN:0140-6736
Container-title:The Lancet
language:en
Short-container-title:The Lancet

Author:

Schmitz Norbert,Pfistner Beate,Sextro Michael,Sieber Markus,Carella Angelo M,Haenel Matthias,Boissevain Friederike,Zschaber Reinhart,Müller Peter,Kirchner Hartmut,Lohri Andreas,Decker Susanne,Koch Bettina,Hasenclever Dirk,Goldstone Anthony H,Diehl Volker

Publisher

Elsevier BV

Subject

General Medicine

Reference30 articles.

1. Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD;Canellos;N Engl J Med,1992

2. Assessment of the Stanford V regimen and consolidative radiotherapy for bulky and advanced Hodgkin's disease: Eastern Cooperative Oncology Group Pilot Study E1492;Horning;J Clin Oncol,2000

3. BEACOPP, a new dose-escalated and accelerated regimen, is at least as effective as COPP/ABVD in patients with advanced-stage Hodgkin's lymphoma: interim report from a trial of the Germany Hodgkin's Lymphoma Study Group;Diehl;J Clin Oncol,1998

4. ASHAP: a regimen for cytoreduction of refractory or recurrent Hodgkin's disease;Rodriguez;Blood,1999

5. The MINE regimen as intensive salvage chemotherapy for relapsed and refractory Hodgkin's disease;Fermè;Ann Oncol,1995

Cited by 975 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Integrating Novel Agents Into the Clinical Management of Classic Hodgkin Lymphoma;JCO Oncology Practice;2024-09-12

2. Hodgkin lymphoma: 2025 update on diagnosis, risk‐stratification, and management;American Journal of Hematology;2024-09-06

3. Advanced stage classic Hodgkin lymphoma (cHL): biology, clinical features, therapeutic approach, and management at relapse;Leukemia & Lymphoma;2024-09-03

4. Clinical and safety outcomes of BeEAM (Bendamustine, Etoposide, Cytarabine, Melphalan) versus CEM (Carboplatin, Etoposide, Melphalan) in lymphoma patients as a conditioning regimen before autologous hematopoietic cell transplantation;BMC Cancer;2024-08-13

5. Effectiveness of biosimilar pegfilgrastim in patients with lymphoma after high-dose chemotherapy and autologous stem cell transplantation: a real-life study;Frontiers in Hematology;2024-07-25